ロード中...
Clinical Outcomes in Carbapenem-Resistant Enterobacteriaceae Infections Treated With Ceftazidime-Avibactam: A Single-Center Observational Study
Introduction Among the several newer beta lactam+beta lactase inhibitors (BL/BLI), ceftazidime-avibactam is the only drug showing activity against OXA-48-like producers. Hence, it is being increasingly used in India to treat infections caused by carbapenem-resistant Enterobacteriaceae (CRE), especia...
保存先:
| 出版年: | Cureus |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Cureus
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7931974/ https://ncbi.nlm.nih.gov/pubmed/33680621 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.13081 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|